These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34141773)

  • 1. Atezolizumab-induced anaphylactic shock in a patient with hepatocellular carcinoma undergoing immunotherapy: A case report.
    Bian LF; Zheng C; Shi XL
    World J Clin Cases; 2021 Jun; 9(16):4110-4115. PubMed ID: 34141773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report: Pembrolizumab as an alternative to atezolizumab following a severe infusion reaction.
    Lee SH; Kim HJ; Bang HJ; Park SJ; Yu JE; Jeong SW; Bae WK
    Front Oncol; 2024; 14():1273043. PubMed ID: 38500659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaphylactic shock in a small cell lung cancer patient receiving atezolizumab therapy: a rare but potentially fatal complication.
    Zhao Y; Peng W; Abbas M; Shi M; Tang Y; Wang L; Yan H
    Invest New Drugs; 2022 Feb; 40(1):209-214. PubMed ID: 34398354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three cases of immune-related hypopituitarism after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
    Furuichi N; Naganuma A; Kaburagi T; Suzuki Y; Hoshino T; Shibusawa N; Horiguchi S; Hatanaka T; Kakizaki S; Uraoka T
    Clin J Gastroenterol; 2023 Jun; 16(3):422-431. PubMed ID: 36821067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
    Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
    Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatal acquired coagulation factor V deficiency after hepatectomy for advanced hepatocellular carcinoma as a possible immune checkpoint inhibitor-related adverse event: a case report.
    Arakaki S; Ono S; Kawamata F; Ishino S; Uesato Y; Nakajima T; Nishi Y; Morishima S; Arakaki S; Maeshiro T; Souri M; Ichinose A; Masuzaki H; Takatsuki M
    Surg Case Rep; 2023 Feb; 9(1):16. PubMed ID: 36729240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab plus bevacizumab-induced intratumoral hemorrhage in a patient with rib metastasis from unresectable hepatocellular carcinoma.
    Mitsuyama Y; Kageyama K; Shinkawa H; Yamamoto A; Jogo A; Sohgawa E; Tanaka S; Takemura S; Kubo S; Ishizawa T; Miki Y
    Radiol Case Rep; 2023 Sep; 18(9):3037-3040. PubMed ID: 37434611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy.
    Tsunemitsu R; Tabuchi M; Sakamoto S; Ogi K; Matsumoto M; Iwata J; Okabayashi T
    Surg Case Rep; 2023 Jun; 9(1):93. PubMed ID: 37266831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corneal Perforation in a Patient Treated with Atezolizumab-Bevacizumab Combination Therapy for Unresectable Hepatocellular Carcinoma.
    Alkharashi MS; Al-Essa RS; Otaif W; Algorashi I
    Am J Case Rep; 2023 Sep; 24():e940688. PubMed ID: 37653721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab-associated myositis in a patient with unresectable hepatocellular carcinoma.
    Baigi T; Brown EN; De La Torre RM; Abu-Shahin FI
    J Oncol Pharm Pract; 2023 Oct; 29(7):1757-1761. PubMed ID: 37282559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe febrile neutropenia and pancytopenia in a patient with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: a case report.
    Chamseddine S; LaPelusa M; Carter K; Nguyen V; Mohamed YI; Sakr Y; Rojas-Hernandez CM; Hatia RI; Hassan M; Goss JA; Elsayes KM; Rashid A; Sun R; Tran Cao HS; Amin HM; Kaseb AO
    J Gastrointest Oncol; 2024 Jun; 15(3):1324-1330. PubMed ID: 38989410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful desensitization to atezolizumab-induced near-fatal anaphylaxis in patients with hepatocellular carcinoma: A case report and literature review.
    Oh JH; Seo KI; Kim HK; Choi GS
    Asia Pac Allergy; 2024 Aug; 14(3):139-142. PubMed ID: 39220574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report: Successful treatment of a patient undergoing haemodialysis with multifocal hepatocellular carcinoma using atezolizumab and bevacizumab.
    Abraham S; Samson A
    Front Oncol; 2023; 13():1279501. PubMed ID: 38239658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.
    Choi B; McBride A; Scott AJ
    Am J Health Syst Pharm; 2019 Oct; 76(21):1749-1752. PubMed ID: 31612928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Camrelizumab-induced anaphylactic shock in an esophageal squamous cell carcinoma patient: A case report and review of literature.
    Liu K; Bao JF; Wang T; Yang H; Xu BP
    World J Clin Cases; 2022 Jun; 10(18):6198-6204. PubMed ID: 35949858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab.
    Sawatari K; Izumi M; Sone R; Hattori T; Sugimoto A; Eguchi Y; Mamoto T
    Respir Med Case Rep; 2022; 36():101579. PubMed ID: 35059287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
    Rizzo A; Ricci AD; Di Federico A; Frega G; Palloni A; Tavolari S; Brandi G
    Front Oncol; 2021; 11():803133. PubMed ID: 34976841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy.
    Xipell M; Victoria I; Hoffmann V; Villarreal J; García-Herrera A; Reig O; Rodas L; Blasco M; Poch E; Mellado B; Quintana LF
    Oncoimmunology; 2018; 7(7):e1445952. PubMed ID: 29900063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
    Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
    Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.